Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Dipeptidyl peptidases 4 (DPP4) inhibitors are a new class of oral anti-hyperglycemic drugs for the treatment of type 2 diabetes (T2DM). They are also called "incretins" because they act by inhibiting the degradation of endogenous incretin hormones, in particular GLP-1, that mediates their main metabolic effects. DPP4 is an ubiquitous protease that regulates not only glucose and lipid metabolism, but also exhibits several systemic effects at different site levels. DPP4 inhibition improves endothelial function, reduces the pro-oxidative and the pro-inflammatory state, and exerts renal effects. These actions are mediated by different DPP4 ligands, such as cytokines, growth factors, neuotransmitters etc. Clinical and experimental studies have demonstrated that DPP4 inhibitors are efficient in protecting cardiac, renal and vascular systems, through antiatherosclerotic and vasculoprotective mechanisms. For these reasons DDP4 inhibitors are thought to be "cardiovascular protective" as well as anti-diabetic drugs. Clinical trials aimed to demonstrate the efficacy of DPP4 inhibitors in reducing cardiovascular events, independent of their anti-hyperglycemic action, are ongoing. These trials will also give necessary information on their safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature
Yan, S. F., Ramasamy, R., & Schmidt, A. M. (2010) · Circulation Research · doi:10.1161/circresaha.109.212217 · Cited by 381
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., & Rotella, C. M. (2005) · Diabetologia · doi:10.1007/s00125-005-1749-8 · Cited by 206
Liu, L., Liu, J., Wong, W. T., Tian, X. Y., Lau, C. W., Wang, Y.-X., Xu, G., Pu, Y., Zhu, Z., Xu, A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195115 · Cited by 179 · cited 9×
“Thus incretins allow a more prolonged and more effective action of endogenous GLP-1 that not only regulates pancreatic hormone metabolism, but also mediates other important effects, mainly in the nervous and cardiovascular systems and in the kidney.”
InfluentialDobrian, A. D., Ma, Q., Lindsay, J. W., Leone, K. A., Ma, K., Coben, J., Galkina, E. V., & Nadler, J. L. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00463.2010 · Cited by 166 · cited 1×
“have studied the effect of sitagliptin on subacute inflammation of the adipose tissue, in a mouse model fed with a high fat diet, for 12 weeks [61].”
Horton, E. S., Silberman, C., Davis, K. L., & Berria, R. (2010) · Diabetes Care · doi:10.2337/dc09-2062 · Cited by 156
Ta, N. N., Schuyler, C. A., Li, Y., Lopes-Virella, M. F., & Huang, Y. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31821e5626 · Cited by 156 · cited 1×
“found that alogliptin treatment, in ApoE2/2 diabetic mice, induced a significant reduction of atherosclerotic lesions and a concomitant reduction of IL-6 and IL-1beta, especially in diabetic mice [63].”
Vittone, F., Liberman, A., Vasic, D., Ostertag, R., Esser, M., Walcher, D., Ludwig, A., Marx, N., & Burgmaier, M. (2012) · Diabetologia · doi:10.1007/s00125-012-2582-5 · Cited by 97
High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV
Marchetti, C., Di Carlo, A., Facchiano, F., Senatore, C., De Cristofaro, R., Luzi, A., Federici, M., Romani, M., Napolitano, M., Capogrossi, M. C., et al. (2012) · Diabetologia · doi:10.1007/s00125-011-2213-6 · Cited by 52 · cited 1×
“Declared none.”
Cited by
Ambrosi, T. H., Scialdone, A., Graja, A., Gohlke, S., Jank, A.-M., Bocian, C., Woelk, L., Fan, H., Logan, D. W., Schürmann, A., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.02.009 · Cited by 856
Incretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03384-1 · Cited by 3
“This reabsorption process occurs through this exchanger (Avogaro et al. 2014; Girardi et al. 2001), and the resultant H + ions are the result of the carbonic anhy-drase enzyme and bicarbonate creation.”
Metadata
- Authors
- Avogaro, A., Kreutzenberg, S., & Fadini, G.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-05-31
- Volume
- 20
- Issue
- 14
- Pages
- 2387-2394
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2098558953
- Cited by
- 45
- References
- 10
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection. https://app.cochat.ai/papers/10.2174/13816128113199990474
- The paper
- Avogaro, A., Kreutzenberg, S., & Fadini, G. (2014). Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990474
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.